Clinical Trials Logo

Filter by:
NCT ID: NCT00143130 Completed - Seizures Clinical Trials

Pregabalin In Partial Seizures Extension Study

PREPS EXT
Start date: April 2005
Phase: Phase 3
Study type: Interventional

To evaluate long-term efficacy and safety of pregabalin (150 to 600mg/day) as adjunctive treatment in patients with partial seizures.

NCT ID: NCT00141427 Completed - Seizures Clinical Trials

Pregabalin In Partial Seizures: An Open-Label, International, Multicenter Add-On Therapy Trial.

Start date: November 2004
Phase: Phase 4
Study type: Interventional

To assess the clinical improvement (change in seizure frequency), safety and tolerability of patients with partial seizures following adjunctive therapy of pregabalin BID in addition to existing standard AEDs.

NCT ID: NCT00141193 Completed - Colorectal Adenoma Clinical Trials

Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)

PRESAP
Start date: February 2001
Phase: Phase 3
Study type: Interventional

This study is a prospective, randomized, double-blind, placebo-controlled, multi-center trial to compare the efficacy and safety of celecoxib 400mg QD versus placebo in reducing the occurrence of new colorectal adenomas post-polypectomy at Month 13 (Year 1) and Month 37 (Year 3) of study drug administration.

NCT ID: NCT00141102 Completed - Osteoarthritis Clinical Trials

Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis

CONDOR
Start date: October 2005
Phase: Phase 4
Study type: Interventional

To determine whether celecoxib is superior to combined therapy with diclofenac and omeprazole in the incidence of clinically significant upper and/or lower gastrointestinal (GI) events in high GI risk subjects with osteoarthritis and/or rheumatoid arthritis.

NCT ID: NCT00136344 Completed - Endophthalmitis Clinical Trials

Study of Antibiotic Prophylaxis for Endophthalmitis Following Cataract Surgery

Start date: September 2003
Phase: N/A
Study type: Interventional

Cataract is the most important cause of visual impairment and decreased mobility in the elderly. While surgery is usually successful, it is also responsible for permanent loss of vision in up to 0.1% of patients due to severe post-operative infection (endophthalmitis). Because of this risk, surgery is typically performed on one eye at a time leaving the patient with a monocular cataract causing considerable visual impairment with reduction in mobility and quality of life. A second operation is required which often takes place up to one year later. It is not known at present whether the post-operative complication of endophthalmitis can be prevented by perioperative use of antibiotics. This randomised study (masked and placebo-controlled for topical levofloxacin and unmasked for intracameral injection of cefuroxime) sets out to test in 4 groups, each of 8,750 cataract surgery patients, if either topical antibiotic (levofloxacin) perioperatively or an intraocular (intracameral) injection of antibiotic (cefuroxime) at the end of phacoemulsification cataract surgery or the combination provides effective prophylaxis of post-operative infection (endophthalmitis) compared to controls in whom perioperative antibiotics are not used. The result will provide a scientific basis for prophylaxis of infection (endophthalmitis) following cataract surgery in Europe as well as an accurate figure for the incidence of endophthalmitis following phacoemulsification cataract surgery in Europe for the first time.

NCT ID: NCT00135577 Completed - Cancer Clinical Trials

Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects

Start date: September 2004
Phase: Phase 2
Study type: Interventional

Study SB-767905/008 was a multicenter study to evaluate the effectiveness and safety of multiple dosage regimens of an investigational drug for the treatment of constipation due to prescription pain medication in participants with cancer pain. Study ABD101684 will serve as an extension to Study SB-767905/008 and offer continued access to blinded investigational product to participants who have completed the original study. The purpose of Study ABD101684 is to evaluate the safety and efficacy of alvimopan compared to placebo in subjects who completed Study SB-767905/008 and elected to participate in this extension study.

NCT ID: NCT00134966 Completed - Parkinson's Disease Clinical Trials

A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa

Start date: August 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to achieve approval for the use of carbidopa/levodopa/entacapone in early Parkinson's disease (PD) by demonstrating that when used as initial levodopa therapy in early PD, carbidopa/levodopa/entacapone provides significantly greater symptomatic benefit than immediate release carbidopa/levodopa administered at the same levodopa dosage level of 100 mg three times a day (t.i.d.).

NCT ID: NCT00134810 Completed - Clinical trials for Myofascial Pain Syndromes

Study to Assess the Efficacy and Safety of Dysport® in Upper Back Myofascial Pain Syndrome

Start date: March 2005
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to determine which is the best dose of a drug known as Dysport to give when treating one's type of upper back pain. The study will also examine the side effects of this treatment and its overall effect on one's disorder.

NCT ID: NCT00134563 Completed - Multiple Sclerosis Clinical Trials

Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis

TEMSO
Start date: September 2004
Phase: Phase 3
Study type: Interventional

The primary objective was to determine the effect of teriflunomide on the frequency of relapses in patients with relapsing multiple sclerosis (MS). Secondary objectives were: - to evaluate the effect of teriflunomide on the accumulation of disability as measured by Expanded Disability Status Scale [EDSS], the burden of disease as measured by Magnetic Resonance Imaging [MRI] and patient-reported fatigue; - to evaluate the safety and tolerability of teriflunomide.

NCT ID: NCT00133952 Completed - Clinical trials for Diabetic Macular Edema

Effect of Ruboxistaurin on Clinically Significant Macular Edema

Start date: August 2005
Phase: Phase 3
Study type: Interventional

The purpose of the study is to test the hypothesis that oral administration of ruboxistaurin will reduce the occurrence of sustained moderate visual loss (SMVL) in patients with clinically significant macular edema. SMVL is defined as a 15 letter or more decrease from baseline in best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity that is sustained for the patient's last 6 months of study participation. The SMVL data from this study will be combined with the SMVL data from Study B7A-MC-MBDL for the purpose of comparing ruboxistaurin to placebo.